- Presentation scheduled for 2:30 pm ET on August 14,
2019 -
VANCOUVER, Aug. 7, 2019 /CNW/ - Sierra Oncology, Inc.
(SRRA), a late-stage drug development company focused on advancing
targeted therapeutics for the treatment of patients with
significant unmet needs in hematology and oncology, today
announced that Dr. Nick Glover,
President and Chief Executive Officer, will present an overview of
the company at 2:30 pm ET on
Wednesday, August 14 at the Wedbush PacGrow Healthcare
Conference being held in New
York.
A live audio webcast and archive of the presentation will be
accessible through the Sierra Oncology website at
www.sierraoncology.com.
About Sierra Oncology
Sierra Oncology is a late stage drug development company focused
on advancing targeted therapeutics for the treatment of patients
with significant unmet medical needs in hematology and
oncology.
Momelotinib, Sierra's lead drug candidate, is a potent,
selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor
with a differentiated therapeutic profile in myelofibrosis
encompassing robust constitutional symptom improvements, a range of
meaningful anemia benefits, including eliminating or reducing the
need for frequent blood transfusions, and comparable spleen control
to ruxolitinib. More than 1,200 subjects have received momelotinib
since clinical studies began in 2009, including more than 800
subjects treated for myelofibrosis. Sierra plans to launch the
MOMENTUM Phase 3 clinical trial in the fourth quarter of 2019 to
support potential registration of momelotinib on a global basis.
Momelotinib is wholly owned by Sierra Oncology and is covered by
patents anticipated to provide potential exclusivity to 2040 in
the United States.
Sierra is also developing a portfolio of DNA Damage Response
(DDR) assets, consisting of SRA737 and SRA141, and is conducting a
campaign intended to seek non-dilutive strategic options to support
their further advancement.
SRA737 is a potent, highly selective, orally bioavailable small
molecule inhibitor of Checkpoint kinase 1 (Chk1), a key regulator
of cell cycle progression and the DDR.
Tumors with high levels of replication stress become reliant on
Chk1 to mitigate the potentially catastrophic consequences of
excess genomic instability. SRA737+LDG, a novel drug combination
where non-cytotoxic low dose gemcitabine (LDG) acts as a potent
extrinsic inducer of replication stress, has demonstrated
preliminary clinical efficacy.
SRA141 is a potent, selective, orally bioavailable small
molecule inhibitor of Cell division cycle 7 kinase (Cdc7) with a
potential novel mechanism of cytotoxicity. Sierra has successfully
completed the IND process with the FDA enabling the commencement of
clinical trials for SRA141 and has designed a potential Phase 1/2
trial with this drug candidate.
Sierra Oncology retains the global commercialization rights to
momelotinib, SRA737 and SRA141.
For more information, please visit www.sierraoncology.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995, including, but not
limited to, statements regarding Sierra Oncology's expectations
from current data, anticipated clinical development activities,
timing of the initiation of MOMENTUM, expected timing of the
execution of, and expected results from, non-dilutive strategic
options, and potential benefits of Sierra Oncology's lead product
candidate and other product candidates. All statements other than
statements of historical fact are statements that could be deemed
forward-looking statements. These statements are based on
management's current expectations and beliefs and are subject to a
number of risks, uncertainties and assumptions that could cause
actual results to differ materially from those described in the
forward-looking statements. Such forward-looking statements are
subject to risks and uncertainties, including, among others, the
risk that Sierra Oncology may be unable to successfully develop and
commercialize product candidates, product candidates may not
demonstrate safety and efficacy or otherwise produce positive
results, Sierra Oncology may experience delays in the preclinical
and anticipated clinical development of its product candidates,
Sierra Oncology may be unable to acquire additional assets to build
a pipeline of additional product candidates, Sierra Oncology's
third-party manufacturers may cause its supply of materials to
become limited or interrupted or fail to be of satisfactory
quantity or quality, Sierra Oncology's cash resources may be
insufficient to fund its current operating plans and it may be
unable to raise additional capital when needed, Sierra Oncology may
be unable to obtain and enforce intellectual property protection
for its technologies and product candidates and the other factors
described under the heading "Risk Factors" set forth in Sierra
Oncology's filings with the Securities and Exchange Commission from
time to time. Sierra Oncology undertakes no obligation to update
the forward-looking statements contained herein or to reflect
events or circumstances occurring after the date hereof, other than
as may be required by applicable law.
View original
content:http://www.prnewswire.com/news-releases/sierra-oncology-to-present-at-the-wedbush-pacgrow-healthcare-conference-in-new-york-300897585.html
SOURCE Sierra Oncology